Sunil Agarwal is Chief Medical Officer at Ultragenyx Pharmaceutical Inc. (RARE). They have made 2 open-market trades across 2 companies since 2015, most recently 2025-06-25.
CIK 0001616640
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SANA | SELL | 2021-09-15 | 2021-09-17 | $26.07 | $3.1M | -12.3% | -17.5% | -33.3% |
| JUNO | SELL | 2017-10-02 | 2017-10-04 | $44.76 | $652K | -4.5% | +30.2% | +5.4% |
| RARE | SELL · 10b5-1 | 2016-07-21 | 2016-07-21 | $52.68 | $34K | +20.1% | +29.2% | +16.8% |
| RARE | SELL · 10b5-1 | 2016-06-20 | 2016-06-21 | $54.16 | $35K | -0.4% | +0.7% | +47.4% |
| RARE | SELL · 10b5-1 | 2016-05-24 | 2016-05-26 | $66.00 | $43K | +3.1% | -31.6% | -7.3% |
| RARE | SELL · 10b5-1 | 2016-04-20 | 2016-04-21 | $70.53 | $46K | -13.4% | -13.9% | -30.3% |
| RARE | SELL · 10b5-1 | 2016-03-22 | 2016-03-24 | $61.45 | $40K | +23.3% | +22.8% | -12.1% |
| RARE | SELL · 10b5-1 | 2016-02-22 | 2016-02-23 | $63.48 | $42K | +4.5% | -1.7% | +8.6% |
| RARE | SELL · 10b5-1 | 2016-01-20 | 2016-01-21 | $72.83 | $43K | -20.9% | -17.1% | -8.3% |
| RARE | SELL · 10b5-1 | 2015-12-22 | 2015-12-24 | $114.81 | $57K | -29.4% | -29.3% | -46.0% |
| RARE | SELL · 10b5-1 | 2015-11-23 | 2015-11-24 | $95.88 | $48K | -29.4% | -6.4% | -41.4% |
| RARE | SELL · 10b5-1 | 2015-10-20 | 2015-10-21 | $85.51 | $55K | -29.4% | -6.4% | -34.3% |
| RARE | SELL · 10b5-1 | 2015-09-22 | 2015-09-24 | $109.51 | $55K | -29.4% | -6.4% | -6.4% |
| RARE | SELL · 10b5-1 | 2015-08-20 | 2015-08-21 | $111.18 | $1.9M | -29.4% | -6.4% | -6.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.